Desmopressin as a Therapy for Nocturnal Enuresis in Patients With Sickle Cell Disease
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Reduction in Bedwetting episodes
研究概览
简要总结
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
详细描述
Night time bedwetting is a common complication of sickle cell disease, and affects up to 30 % of children . Desmopressin is an oral medication that increases water reabsorption in the kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys could cause permanent damage and may make this treatment ineffective in sickle cell disease. This trial will inform pediatric sickle cell doctors if desmopressin is an appropriate treatment for bed wetting in the investigators patients.
This work is being continued on study ID: 2020-11268.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 8 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Hemoglobin SS, SC, SB0thal or SB+thal
- •Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.
- •Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)
排除标准
- •Patients with developmental delay or neurologic dysfunction secondary to stroke.
- •Patients with hypertension or underlying renal disease.
- •Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.
- •Patients with daytime urinary incontinence
- •Patients with glucosuria on urinalysis.
- •Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.
- •Patients who are pregnant.
- •Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).
研究组 & 干预措施
Desmopressin
0.2mg tablets, dose titrated to effect
干预措施: Desmopressin (Drug)
结局指标
主要结局
Reduction in Bedwetting episodes
时间窗: Baseline and 4 weeks
To prospectively assess if the use of desmopressin in patients with sickle cell disease and nocturnal enuresis will decrease the number of nighttime episodes of enuresis by 50% after initiating DDAVP at 0.4 mg nightly dose with dose escalation as clinically indicated compared to the control group.
次要结局
- Quality of life measure(Baseline and 4 weeks)
- Reduction in Nighttime awakenings(Baseline and 4 weeks)
- Reduction in Daytime Fatigue(Baseline and 4 weeks)
研究者
Kerry Morrone
Assistant Professor of Pediatrics
Montefiore Medical Center